About Baseimmune

Baseimmune develops vaccines and immunotherapies by combining computational protein design with advanced engineering. The company creates bespoke antigens that tackle chronic diseases where traditional methods fail, using deep learning to predict pathogen mutations and generate longer lasting, multi strain solutions. Founded by Oxford scientists, the platform addresses disease complexity that conventional approaches cannot solve. Their work centres on active immunotherapies for fibrosis and infectious diseases. Baseimmune serves clinicians and patients who need treatments that remain effective despite evolving biological challenges. The company transforms outcomes for diseases once considered too complex for immunotherapy.